Literature DB >> 29230149

Improving the Treatment of Irritable Bowel Syndrome With the Rome IV Multidimensional Clinical Profile.

Douglas A Drossman1.   

Abstract

Entities:  

Year:  2017        PMID： 29230149      PMCID： PMC5717885     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Functional gastrointestinal disorders: what's new for Rome IV?

Authors:  Douglas A Drossman
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-08-10

2.  Updates to the Rome Criteria for Irritable Bowel Syndrome.

Authors:  Lin Chang
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-05

Review 3.  What's new in Rome IV?

Authors:  J Tack; D A Drossman
Journal:  Neurogastroenterol Motil       Date:  2017-03-17       Impact factor: 3.598

4.  Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV.

Authors:  Douglas A Drossman
Journal:  Gastroenterology       Date:  2016-02-19       Impact factor: 22.682
  4 in total
  3 in total

1.  Linaclotide utilization and potential for off-label use and misuse in three European countries.

Authors:  Javier Cid-Ruzafa; Brian E Lacy; Anna Schultze; Mai Duong; Yi Lu; Mireia Raluy-Callado; Robert Donaldson; Darren Weissman; Ainhoa Gómez-Lumbreras; Dan Ouchi; Maria Giner-Soriano; Rosa Morros; Ahunna Ukah; Daniel Pohl
Journal:  Therap Adv Gastroenterol       Date:  2022-06-11       Impact factor: 4.802

2.  Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome.

Authors:  Giovanni Barbara; Madhusudan Grover; Premysl Bercik; Maura Corsetti; Uday C Ghoshal; Lena Ohman; Mirjana Rajilić-Stojanović
Journal:  Gastroenterology       Date:  2018-11-28       Impact factor: 22.682

3.  Cannabinoid Receptors Overexpression in a Rat Model of Irritable Bowel Syndrome (IBS) after Treatment with a Ketogenic Diet.

Authors:  Isabella Gigante; Valeria Tutino; Francesco Russo; Valentina De Nunzio; Sergio Coletta; Raffaele Armentano; Alberto Crovace; Maria Gabriella Caruso; Antonella Orlando; Maria Notarnicola
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.